Vassiliki A. Papadimitrakopoulou
Pfizer (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, RNA modifications and cancer, Lung Cancer Research Studies
Most-Cited Works
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
- → STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma(2018)1,562 cited
- → Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study(2016)1,385 cited
- → Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities(2015)897 cited
- → The BATTLE Trial: Personalizing Therapy for Lung Cancer(2011)885 cited
- → Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer(2015)660 cited